Suchergebnisse - "Ofran, Yishai"

PubPharm (141)

91

Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation

enthalten in: British journal of haematology | 2019

von Ofran, Y. | Beohou, E. | Labopin, M. | +9

92

The role of specialized hospital units in infection and mortality risk reduction among patients with hematological cancers

enthalten in: PloS one | 2019

von Carmen, R. | Yom-Tov, G. | Van Nieuwenhuyse, I. | +2

93

Grb2 regulates the proliferation of hematopoietic stem and progenitors cells

enthalten in: Biochimica et biophysica acta. Molecular cell research | 2017

von Frelin, C. | Ofran, Y. | Ruston, J. | +8

94

Activated kinases in ALL : time to act

enthalten in: Blood | 2017

von Ofran, Y.

CommentOn: Blood. 2017 Jun 22;129(25):3352-3361. - PMID 28408464

95

Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study

enthalten in: Annals of hematology | 2017

von Ram, R. | Gatt, M. | Merkel, D. | +5

96

BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options

enthalten in: Blood reviews | 2017

von Ofran, Y. | Izraeli, S.

97

Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation—a retrospective national multicenter study

enthalten in: Annals of hematology | 2017

von Ram, R. | Gatt, M. | Merkel, D. | +5

98

Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation—a retrospective national multicenter study

enthalten in: Annals of hematology | 2017

von Ram, R. | Gatt, M. | Merkel, D. | +5

99

Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation—a retrospective national multicenter study

enthalten in: Annals of hematology | 2017

von Ram, R. | Gatt, M. | Merkel, D. | +5

100

Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

enthalten in: Annals of hematology | 2016

von Mittelman, M. | Filanovsky, K. | Ofran, Y. | +10